Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B Cell Response to Pneumovax in Healthy Adults
NCT02126384Completed
- Sponsor
- Inserm
- Start
- Nov 2014
- Primary completion
- Apr 2016
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Inserm. Primary endpoint: Identification of the precursor of B lymphocytes at Day 7. Started Nov 2014; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02126384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126384.